ASCO GU Symposium 2021
In-depth coverage of the 2021 ASCO GU Symposium
Efortumab vedotin prolonged OS in patients who had previously received chemotherapy and checkpoint inhibitors.
The phase 3 CLEAR trial showed improved OS for lenvatinib plus pembrolizumab as first-line therapy for advanced RCC.
Nivolumab improves disease-free survival, non-urothelial tract recurrence-free survival, and metastasis-free survival.
The phase 2 SWOG 1500 trial showed improvement in progression-free survival for cabozantinib in metastatic papillary RCC.
Relugolix represents a new oral option for GnRH receptor antagonism.
Establishing Cabazitaxel as third-line therapy for metastatic castration-resistant prostate cancer by the phase 4 CARD trial.
177Lu-PSMA-617 was able to generate more PSA responses of at least 50% reduction compared to taxane cabazitaxel in mCRPC.
Adding enzalutamide to androgen deprivation therapy improved progression-free survival in hormone-sensitive prostate cancer.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.